XML 80 R70.htm IDEA: XBRL DOCUMENT v3.21.1
INVESTMENTS - RELATED PARTIES (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 12, 2021
Feb. 25, 2021
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Mar. 09, 2021
Net unrealized gain (loss) on derivative securities, related party     $ 2,969,170 $ (1,242,094)      
Provision for credit losses     1,000,000      
Avalanche International Corp. [Member]              
Unrealized gain (loss) on its investment     1,900,000   $ (1,100,000)    
Net unrealized gain (loss) on derivative securities, related party     $ 3,000,000        
Description of market capitalizations     Based on historical stock prices for similar technology companies with market capitalizations under $100 million.        
Avalanche International Corp. [Member] | Common Stock [Member]              
Closing price of stock     $ 0.82   $ 0.50    
Number of shares owned     999,175        
Avalanche International Corp. [Member] | Convertible Promissory Note [Member]              
Convertible promissory note aggregate principal amount     $ 12,500,000        
Avalanche International Corp. [Member]              
Interest income from related party     0 0      
Net unrealized gain (loss) on derivative securities, related party       $ 1,200,000      
Avalanche International Corp. [Member] | Philou Ventures, LLC [Member]              
Convertible promissory note aggregate principal amount     $ 13,900,000        
Conversion price (in dollars per share)     $ 0.50        
Interest rate     12.00%        
Warrant term     5 years        
Number of warrants purchased     27,800,000        
Avalanche International Corp. [Member] | Philou Ventures, LLC [Member] | Ownership [Member]              
Ownership percentage     18.00%        
Alzamend. [Member]              
Short-term advance     $ 750,000        
Convertible promissory note aggregate principal amount     $ 50,000        
Conversion price (in dollars per share)     $ 3.00        
Interest rate     8.00%        
Warrant term     5 years        
Number of warrants purchased     16,667        
Fair value of common stock     $ 1.50        
Alzamend. [Member] | Securities Purchase Agreement [Member]              
Investment in common stock and warrants $ 10,000,000            
Funded amount $ 4,000,000            
Description of reamaining funded amount The remaining $6.0 million will be funded upon Alzamend achieving certain milestones related to the U.S. Food and Drug Administration approval of Alzamend’s Investigational New Drug application and Phase 1a human clinical trials for Alzamend’s lithium based ionic cocrystal therapy, known as AL001.            
Description of agreement Alzamend has agreed to sell up to 6,666,667 shares of its common stock to DP Lending for $10.0 million, or $1.50 per share, and issue to DP Lending warrants to acquire up to 3,333,334 shares of Alzamend common stock with an exercise price of $3.00 per share.            
Convertible promissory note aggregate principal amount             $ 800,000
Unrealized gain (loss) on its investment $ 236,000            
Fair value of common stock             $ 1.14
Alzamend. [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]              
Value of shares issued         $ 252,000    
Number of shares acquired         427,888    
Alzamend. [Member] | DPW Holdings [Member] | Securities Purchase Agreement [Member]              
Convertible promissory note aggregate principal amount     $ 800,000        
Alzamend. [Member] | DPW Holdings [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]              
Value of shares issued           $ 252,000  
Number of shares acquired           427,888  
Ault & Company, Inc. [Member] | 8% Secured Promissory Note [Member]              
Principal amount   $ 2,500,000          
Interest rate   8.00%          
Due and payable date   Feb. 25, 2022